NYSE:TEVA   Teva Pharmaceutical Industries Limited
TEVA has been a repair story now for many years. With litigation in the process of being resolved, debt burdens of $2 bn. per year appear manageable with cash flow - TEVA is moving away from a debt/litigation story
to an equity story. Cash Flow of $3bn + per year, Net Income of ~ 2bn.+.... warrant a blended Intrinsic Value of ~ $22 per share. TEVA's technicals show a textbook double bottom with positive divergence. Reverting to trends and fibonacci levels confirm $22 target.
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。